Epigenetic mechanisms have been proposed to play a role in the etiology of autism. This hypothesis is supported by the discovery of increased MECP2 promoter methylation associated with decreased MeCP2 protein expression in autism male brain. To further understand the influence of female X chromosome inactivation (XCI) and neighboring methylation patterns on aberrant MECP2 promoter methylation in autism, multiple methylation analyses were performed on brain and blood samples from individuals with autism. Bisulfite sequencing analyses of a region 0.6 kb upstream of MECP2 in brain DNA samples revealed an abrupt transition from a highly methylated region in both sexes to a region unmethylated in males and subject to XCI in females. Chromatin immunoprecipitation analysis demonstrated that the CCCTC-binding factor (CTCF) is bound to this transition region in neuronal cells, consistent with a chromatin boundary at the methylation transition. Male autism brain DNA samples displayed a slight increase in methylation in this transition region, suggesting a possible aberrant spreading of methylation into the MECP2 promoter in autism males across this boundary element. In addition, autistic female brain DNA samples showed evidence for aberrant MECP2 promoter methylation as an increase in the number of bisulfite sequenced clones with undefined XCI status for MECP2 but not androgen receptor (AR). To further investigate the specificity of MECP2 methylation alterations in autism, blood DNA samples from females and mothers of males with autism were also examined for XCI skewing at AR, but no significant increase in XCI skewing was observed compared to controls. These results suggest that the aberrant MECP2 methylation in autism brain DNA samples is due to locus-specific rather than global X chromosome methylation changes.
Introduction
Autism is a severe neurodevelopmental disorder affecting, according to most recent estimates, around 1 in 150 individuals [Rice et al., 2007] . Autism is characterized by deficits in social interaction and communication and by gains in restricted and repetitive interests and behaviors. Although a large body of evidence indicates a major role for genetic variation, several observations point to an additional role for epigenetic variation in the etiology of autism. Decreased homologous 15q11-13 chromosome pairing, decreased H3K9 trimethylation, increased H3K9 acetylation, and aberrant UBE3A methylation have been observed in autism brain [Jiang et al., 2004; Thatcher & Lasalle, 2006; Thatcher, Peddada, Yasui, & Lasalle, 2005] .
The higher incidence of autism in males (4:1 male to female) suggests the involvement of the sex chromosomes and possibly changes in epigenetic regulatory mechanisms that differ between the sexes. X chromosome inactivation (XCI) is a random process by which the majority of genes on one of the two X chromosomes present in females are silenced by an epigenetic mechanism [Lyon, 1961] . Increased XCI skewing has been observed in several human diseases with relevance to autism, such as Rett syndrome [Huppke et al., 2006; Knudsen et al., 2006] and X-linked mental retardation (MR) [Plenge, Stevenson, Lubs, Schwartz, & Willard, 2002] . Increased skewing can result from multiple mechanisms including X-linked mutations and reduction in the pool of cells at the time of XCI in early embryogenesis [Brown & Robinson, 2000] . Skewed X inactivation was previously reported in autism female blood [Talebizadeh, Bittel, Veatch, Kibiryeva, & Butler, 2005] , but this report is yet to be independently replicated or examined in additional cell types. XCI skewing ratios in blood have been reported to be significantly correlated with those from brain [Bittel et al., 2007] , but XCI ratios in autism brain have not been previously determined.
MECP2 is a key epigenetic regulator, mutations of which cause the pervasive developmental disorder, Rett syndrome [Amir et al., 1999] . Previously, we demonstrated a defect in MeCP2 expression in 79% of autism cerebral cortex samples [Nagarajan, Hogart, Gwye, Martin, & Lasalle, 2006; Samaco, Nagarajan, Braunschweig, & LaSalle, 2004] . Decreased MeCP2 expression correlated with increased MECP2 promoter methylation in male brain samples. Here, we examine possible explanations for aberrant MECP2 promoter methylation in males by defining the methylation boundary 0.6 kb upstream of MECP2 that corresponds to a binding site for the chromatin boundary factor CTCF. Furthermore, we examined X inactivation patterns in DNA samples isolated from autism female brain and blood cells from mothers of males with autism, hypothesizing that one manifestation of genetic and epigenetic dysregulation in autism might be altered X inactivation.
Materials and Methods

Biological Samples
Frozen frontal cerebral cortex (Brodmann Area 9 (BA9)) samples were obtained with assistance of the Autism Tissue Program from the University of Maryland Brain and Tissue Bank for Neurodevelopmental Disorders, the Harvard Brain Tissue Resource Center, and the University of Miami Brain and Tissue Bank for Neurodevelopmental Disorders. Red blood cell (RBC) pellets containing polymorphonuclear (PMN) cells were obtained from the UC Davis Childhood Autism Risks From Genetics and Environment (CHARGE) study, a large collaborative investigation of genetic, epigenetic, and environmental factors in autism [Hertz-Picciotto et al., 2006] . Participants in the CHARGE study are a population-based sample of children 2-5 years of age from four groups: with autism, with developmental delays (DD), with autism spectrum disorders (ASD), and with typical development. Affected children and their families are recruited from a state-funded system that provides services for persons with developmental disabilities; controls with typical development are randomly sampled from state birth files, with frequency matching by age, gender, and geographic area to autism cases. All autism diagnoses were confirmed by administration of the standardized instruments: Autism Diagnostic Interview-Revised [Le Couteur, Lord, & Rutter, 2003] and Autism Diagnostic Observation Schedules [Lord, Rutter, DiLavore, & Risi, 2000] .
DNA Purification
DNA was purified from all samples with the PureGene kit (Qiagen, Valencia, CA) as per manufacturer's instructions. RBC pellets were cleared of RBCs by two to three washes in hypotonic RBC lysis solution. If necessary, samples were concentrated with microcon columns (Millipore, Temecula, CA).
Bisulfite Sequencing
Frontal cortex (BA9) genomic DNA was isolated from frozen postmortem human samples using the PureGene kit (Qiagen). Approximately 1 mg of frontal cortex genomic DNA was used for bisulfite conversion with the CpGenome kit (Millipore) following the manufacturer's instructions. Briefly, DNA samples were treated overnight at 551 with sodium bisulfite, desalted, desulfonated, and eluted in 20 mL TE. One mL of converted DNA was used for bisulfite polymerase chain reaction (PCR).
Bisulfite primers were designed using the online tool Methprimer (http://www.urogene.org/methprimer/index.html) [Li & Dahiya, 2002] . Primers for MECP2 bisulfite region I: F: GTTAGGTTTTAGGGTGGGTAATTTT, R: CCCCTCCAACTATTAATTAACTACTTTC; MECP2 bisulfite region II: F: GAGGTTTTGGTATGTATTTTTTTT, R: ATTACC CACCCTAAAACCTAAC; androgen receptor (AR): F: GAGTTTTTTAGAATTTGTTTTAGAG, R: AACCAAATAACC TATAAAACCTCTAC. Primers were designed to regions without CpG sites to avoid amplification bias of methylated vs. unmethylated. No polymorphisms were observed in the population analyzed for amplified regions from MECP2 bisulfite region I or II. A 50 mL volume PCR reaction was performed with 2.5 U Roche FastStart High Fidelity Taq, 1 Â Roche FastStart High Fidelity Reaction Buffer (with 1.8 mM MgCl 2 ,) 0.2 mM of each dNTP, and 1 Â dimethyl sulfoxide (Roche, Indianapolis, IN). PCR products were gel purified with the Qiaquick Gel Purification kit (Qiagen) and ligated overnight at 41C with the pGEM-T-Easy kit (Promega, Madison, WI). Two to five microliters of the ligation was used to transform JM109 competent cells (Promega) and bacteria were plated on LB ampicillin. White colonies were picked and grown up in overnight LB Amp cultures. Plasmids were purified with the Qiaprep kit (Qiagen) and tested for presence of the correct insert with a NotI digest (New England Biolabs, Ipswich, MA). Positive plasmids were sequenced using the T7 promoter sequencing primer. Ten to twenty colonies were sequenced for each brain sample in order to obtain a sufficient sampling of allele-specific methylation patterns.
XCI Assay
XCI assay was performed as described [Beever et al., 2003] with some modifications. Brain or RBC pellet genomic DNA was resuspended in TE to 100 ng/mL. One hundred and fifty nanograms of this DNA was digested with 2 U RsaI or 2 U RsaI15 U HpaII in a final volume of 10 mL. Both enzymes were purchased from New England Biolabs. Samples were incubated overnight at 371C and during the next day 5 U HpaII was added to RsaI1HpaII reactions. The reaction was again incubated for 3 hr at 371C to insure complete digestion. Completeness of digestion was confirmed by PCR of 5 0 UTR of MIC2, which escapes X inactivation in females and is therefore always unmethylated [Goodfellow et al., 1988] . MIC2 PCR was performed at 33 cycles using Invitrogen Taq (Carslbad, CA) with an annealing temperature of 621C. The PCR products were visualized on a 1.5% agarose gel using Sybr-Gold (Invitrogen). If any band was observed in an RsaI1HpaII reaction, the digest was repeated and tested again.
The human AR (aka HUMARA) 5 0 end was PCR amplified from the digested samples using 30 cycles with Invitrogen Taq at an annealing temperature of 621C. The forward primer was 5 0 labeled with HEX. Amplicons were diluted 1:2-1:8, and capillary electrophoresis fragment analysis was performed on an ABI3100 (Applied Biosystems, Foster City, CA) with a ROX500 size standard. Allele sizes and peak areas were determined with the PeakScanner software package (Applied Biosystems). For any sample found to have 480% (or o20%) skewing, the assay was repeated, and results of both assays were averaged.
XCI skewing was calculated by measuring peak area of digested and undigested AR PCR products. Since PCR bias may result in preferential amplification of some AR alleles, the peak areas of digested samples were normalized to undigested samples. The degree of skewing was calculated with the formula (d1/u1)/(d1/u11d2/u2), where d1 and d2 are the peak areas of the smaller digested allele and the larger digested allele, respectively, and u1 and u2 are the undigested peak areas. Alleles close in size would result in shadow bands from one overlapping the main bands of the other. For such cases, peak areas were adjusted by assuming that the shadow band represented 30% of the peak area of the main allele. Statistical analysis was performed using a Fisher's exact test.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed using a protocol adapted from de Belle, Cai, and KohwiShigematsu [1998] . Briefly, chromatin was prepared from formaldehyde crosslinked, phorbol myristate acetatedifferentiated SH-SY5Y neurons and purified by urea gradient centrifugation. Purified chromatin was then digested with EarI and XcmI restriction enzymes (NEB, Beverly, MA) then immunoprecipitated (IP) with anti-CTCF (Upstate, Lake Placid, NY) or control antibody. Ten percent of the total chromatin was reserved as input for PCR analysis. Chromatin/antibody complexes were washed extensively, digested with proteinase K, and extracted with phenol/chloroform prior to precipitation of purified DNA from solution. DNA from CTCF IP, control IP, and input was resuspended in 20 mL of 1 Â TE and amplified with MECP2 promoter primers (F: aggctcggatgaaataatgc and R: aggctcggatgaaataatgc) using 28, 30, 32, 34, and 36 cycles of 951C for 30 sec, 571C for 30 sec, 721C for 30 sec with a 10 min 951C pre-incubation and a 10 min 721C post-incubation. Amplicons were resolved by 1.5% agarose gel electrophoresis and visualized by Sybr-Gold (Invitrogen) staining. Gel images were acquired using a Fluorchem (Alpha Innotech, Santa Leandro, CA) gel documentation system.
Results
A Boundary Region for Methylation Differences Observed in MECP2 Upstream Regulatory Region
Our previous investigation demonstrated that the aberrant MECP2 methylation observed in autism male brain samples was most frequent in two 5 0 sites (sites 1 and 3 of bisulfite region I, Fig. 1A ) [Nagarajan et al., 2006] . In addition, site 3 showed methylation specific to autism brain (filled circle with ''A'' in Fig. 1A ). To determine if more 5 0 regulatory CpG sites exhibited aberrant DNA methylation, bisulfite primers were designed to the adjacent region, spanning À700 to À509 bp and containing six CpG sites (bisulfite region II, Fig. 1A ). Bisulfite sequencing of this region was performed on DNA isolated from cerebral cortex from autism and control samples. Figure 1B , C shows the results for total percent methylation of bisulfite region II, and demonstrate that these regions are highly methylated but variable in both male and female brain DNA samples. The variability in methylation of bisulfite region II was independent of age or gender (Fig. 1B) . Autism and control brain DNA samples did not show significant differences in total percent methylation of bisulfite region II, but there was a trend toward higher methylation in male autism samples. Interestingly, in the analysis of percent methylation of each of the six CpG sites in this region (A-F, Fig. 1A) , sites A-D showed significantly higher methylation than the 3 0 sites E and F in male samples (Po0.0001, Fig. 1D ). This abrupt difference in methylation suggests the presence of an insulator element or chromatin boundary (represented as a hatched bar in Fig. 1A ). Methylation of each CpG site was slightly increased in autism samples, although none reached statistical significance. Site F, at À533 bp, was nearly significantly increased in autism brain DNA samples (P 5 0.07).
Autism and control females showed very similar methylation patterns at individual sites within bisulfite region II (Fig. 1E) . Site E demonstrated approximately 50% methylation expected for XCI, while sites A-D showed 70-80% methylation, suggesting methylation of both active and inactive alleles for these four sites. Similar to male samples (Fig. 1D) , sites A-D exhibited significantly higher methylation than sites E and F for control female brain DNA samples (Po0.0001, Fig. 1E ). No significant differences were observed between autism and control females for any of the six CpG sites in bisulfite region II.
The DNA sequence between MECP2 sites D and F contained a putative binding site for the chromatin boundary factor CTCF [Filippova et al., 1996] . In order to determine if CTCF binds to this region in neurons, ChIP was performed in the human neuroblastoma cell line SH-SY5Y. Figure 1F shows that ChIP with an anti-CTCF antibody specifically enriched MECP2 (À595 to À389) over input control, while a nonspecific antibody control (IgG) did not. These results demonstrate that CTCF binds to the methylation transition region in human neuronal cells and suggest that CTCF may mark the boundary of methylation on the active allele of MECP2.
Aberrant Methylation Status for MECP2 in Female Autism Brain Samples Revealed by Bisulfite Sequencing
In order to separate active and inactive X chromosome alleles in female brain DNA samples, we analyzed individual clones from bisulfite sequencing for the number of CpG sites methylated. Both regions from the MECP2 promoter (Fig. 1A) were analyzed as well as a highly characterized region of AR used for the XCI assay. At X-linked promoters subject to XCI, the inactivated X (Xi) tends to be methylated while the active X (Xa) is unmethylated in females, whereas the single X in males is unmethylated and active. Due to the presence of both inactive and active X chromosomes in female samples, we observed both hypo-and hypermethylated clones. For MECP2, however, control female brain DNA samples showed greater than the expected hypermethylated alleles (Supplementary Fig. 1) , likely due to a bias toward the methylated allele in the PCR reaction following bisulfite conversion for this highly CpG-rich promoter ( Fig. 2A, B, Supplementary  Fig. 1 ). The graphs in Figure 2 were used to divide clones as: Xa alleles, namely those with no CpG sites methylated; Xi alleles with 450% of maximum methylated sites; and a third infrequent category of clones that were not clearly Xa or Xi (X?). For both MECP2 promoter regions, autism females showed an increase in the percentage of alleles with undefined XCI status compared to controls, although for AR control the percentage of X? alleles was low in both autism and controls (Fig. 2C, D) . The presumed aberrant methylation in X? clones for autism females was not specific to one site but was spread throughout the different possible CpG sites for both MECP2 regions I and II (Fig. 2E, F) . While these data are suggestive of aberrant methylation of the MECP2 promoter in autism females, problems with bias toward themethylated allele in control female DNA samples with the bisulfite sequencing assay complicate the analyses.
XCI in Autism Female Frontal Cortex
Since AR showed the expected patterns of XCI methylation in autism brain DNA samples, we decided to use the PCR-based XCI assay at AR that is commonly used to assess XCI ratios and determine skewed XCI in females. Skewed XCI was previously reported in a small study of autism female blood cells [Talebizadeh et al., 2005] but not replicated in a much larger recent study [Gong et al., 2008] . To date, XCI has not been described in DNA samples isolated from autism brain. We characterized XCI in autism brain DNA samples with the HpaII AR methylation assay. Table I gives XCI in DNA samples obtained from female postmortem frontal cortex and blood. DNA samples from female controls displayed a normal range of XCI values, ranging from 39.9 to 66.1%, with brain and blood-derived DNA samples showing similar ranges. DNA isolated from females with autism had a comparable range of values, and no individual from either group displayed skewed X inactivation. Although the small sample size precludes definitive conclusions, highly skewed X inactivation does not appear to be frequent in female autism frontal cortex or blood.
Blood XCI Patterns in Mothers of Males With Autism
As one possible explanation for aberrant methylation patterns observed in DNA samples isolated from autism males, we hypothesized that epigenetic dysregulation of the maternally inherited X chromosome could result in aberrant methylation in male offspring. This dysregulation might be observed as an incomplete erasure of methylation patterns on the X chromosome in oocytes, which are the origin of the single X chromosome in Figure 1 . Analysis of an upstream region of MECP2 reveals a methylation boundary element. (A) Schematic of MECP2 promoter regions analyzed by bisulfite sequencing. Vertical lines indicate CpG sites, designated as A-F for bisulfite region II and 1-15 for bisulfite region I. The hatched bar depicts the location of the boundary between methylated and unmethylated regions on the active X chromosome in males and females. Methylation sites are shown as filled circles and the filled circle with an ''A'' represents an autism-specific methylation site previously described [Nagarajan et al., 2006] . (B) The total percent methylation of all sites in bisulfite region II is graphed for each brain sample, designated as control males, autism males, control females, and autism females. MECP2 region II shows a high degree of variable methylation independent of age, gender, or clinical status. (C) The total percent methylation for MECP2 bisulfite region II is shown with each category grouped, showing an only modest nonsignificant increased methylation in females compared to males and no significant difference between autism and control. (D) Male brain samples were compared for percent methylation of each CpG site within MECP2 bisulfite region II (A-F). While no significant differences were observed between autism and control males in the highly methylated sites A-D, there was an abrupt transition observed between sites D and E from a highly methylated region to a mostly unmethylated region at sites E and F. Control and autism brain samples showed significantly higher % DNA methylation of combined sites A-D compared to sites E and F by t-test (Po0.0001). Interestingly, autism males showed a trend of increased methylation (P 5 0.07) at site F which borders the sites in bisulfite region I previously shown to have increased methylation in autism males [A and Nagarajan et al., 2006] . (E) ChIP using chromatin isolated from SH-SY5Y and a specific anti-CTCF antibody or nonspecific antibody (IgG control). ''Total DNA'' represents nonmanipulated genomic DNA from SH-SY5Y cells, while ''input'' is the DNA sample isolated from chromatin but without immunoprecipitation. The anti-CTCF (but not IgG control) showed specific enrichment of MECP2 (À595 to À389) over input. (F) Female brain samples were compared for percent methylation of each CpG site within MECP2 bisulfite region II (A-F). Similar to male samples, no significant differences were observed between autism and control females, and sites A-D were methylated at higher than the expected 50% methylation (hatched line), demonstrating partial methylation of the active allele, as in males. Similar to male samples, sites A-D combined had significantly higher % methylation than sites E and F combined for female control and autism brain samples (Po0.0001). ChIP, chromatin immunoprecipitation.
males. X chromosome epigenetic dysregulation in mothers of male offspring might be reflected by skewed XCI in maternal somatic tissues such as blood. Alternatively, skewed XCI in such mothers could result from protective inactivation of X-linked mutations, which can be passed on to affected males. Supplementary Fig. 1 ). Histograms represent the distribution of percentage of clones based on degree of methylation. The bimodal peaks observed at all three loci are consistent with X chromosome inactivation. Clones with no sites methylated are designated as clear active alleles (Xa), clones with 450% of maximum number of methylated sites are designated as inactive (Xi), and the intervening clones as potentially undefined XCI status (X?). (A) MECP2 region I has a maximum of 14 out of 15 possible methylation sites and control females show a clear bimodal peak between Xa and Xi, although there was an inherent bias toward Xi clones (7-14 sites methylated) for this highly CpG dense promoter. (B) MECP2 region II has six possible methylation sites and more clones within the undefined XCI (X?) category (one to three sites methylated). (C) The control X-linked gene AR has a maximum of 9 out of 10 possible methylation sites. Although most clones from AR fell clearly into either Xa or Xi categories, the number of methylated sites on the inactive X (Xi) was variable, ranging from five to nine sites and no clones showing complete methylation of all ten sites. (D) The total percentage of undefined XCI (X?) clones for autism and control females is graphed for each of the three loci. Interestingly, both MECP2 loci (but not AR) show an increase in X? clones for autism compared to control females, suggesting aberrant methylation of MECP2 in females with autism. (E and F) To examine the possibility of site specificity of methylation in clones showing undefined XCI status, the frequency of methylation of each possible CpG site is graphed for region I (E) and region II (F) only for X? clones. AR, androgen receptor.
Using blood samples obtained from the UC Davis CHARGE study [Hertz-Picciotto et al., 2006] , we extracted genomic DNA from RBC pellets from four groups of mothers, specifically those having: (1) sons with autistic disorder (AD); (2) sons with the broader phenotype of ASD; (3) sons with DD; and (4) typically developing (TD) sons. Sample numbers and characteristics are given in Table II . The RBC pellets contain mostly enucleated erythrocytes and a smaller number of PMN cells, which we believe to be an ideal cell type for studying XCI because it does not undergo the cycling and clonal expansion common to lymphocytes. XCI patterns in DNA samples from control mothers (those with TD sons) are shown in Figure 3 . A broad range of XCI values was observed, with some samples exhibiting skewed (o15 or 485%) or highly skewed (o5 or 495%) XCI. AD, ASD, and DD mothers displayed similar overall XCI patterns compared to controls, without any significant differences between groups (Table II) . We conclude that XCI ratios are within the normal range in DNA samples from mothers of sons with autism or ASD, at least in the cell types under examination.
We next hypothesized that mothers with skewed XCI would be observed to more frequently transmit the preferentially inactivated allele to sons with autism compared to TD sons, perhaps as a result of preferential inactivation of a deleterious X-linked mutation linked to AR. RBC pellet DNA was obtained for sons of mothers with skewed XCI 485:15 and o15:85. The size of the AR allele (which is inherited from one of the alleles present in the mother) was determined by capillary electrophoresis and is given in Table III . Males with mothers displaying skewed XCI inherited both preferentially inactivated (skewed) and activated AR alleles, suggesting that protective skewing against X-linked mutations near AR is not specifically preferential in mothers of sons with autism, at least not in this small sample of primarily simplex cases.
Discussion
Epigenetic defects, such as aberrant promoter methylation, can influence gene expression and result in pathological phenotypes, especially during tumorigenesis. As an example of an epigenetic defect observed in autism, we previously reported increased MECP2 promoter methylation in autism male frontal cortex that correlated with reduced MeCP2 expression in the frontal cortex [Nagarajan et al., 2006] . In this study, we investigated several potential causes of aberrant MECP2 promoter methylation. First, we identified a novel boundary element 600 kb upstream of MECP2, suggesting the potential for methylation spreading from this boundary in males with autism exhibiting aberrant downstream promoter methylation. Second, we divided active and inactive alleles of MECP2 and AR in female brain samples and demonstrated evidence suggestive of aberrant MECP2 promoter methylation in females with autism compared to controls. Third, we provided evidence against skewed XCI as being a common epigenetic occurrence in females with autism or the mothers of males with autism. These results are novel and informative in understanding the extent of X-linked epigenetic alterations in the inheritance of autism. Chromatin boundary elements are important epigenetic determinants in maintaining active promoters as separate from neighboring inactive DNA. The methylation boundary element we identified approximately 600 bp upstream of MECP2 contains several consensus binding sites for the known boundary element CTCF and here we directly demonstrate that CTCF binds to this region in human neuroblastoma cells. Since binding of CTCF is sensitive to DNA methylation, it is an excellent candidate for discriminating methylated from unmethylated sequences [Lewis & Murrell, 2004] . Furthermore, since CTCF binding also protects boundary elements from further methylation, CTCF binding could serve to maintain the active unmethylated MECP2 promoter free of the high degree of methylation observed in the immediately adjacent 5 0 region. The trend for increased methylation of autism male DNA samples for two sites within the chromatin boundary region suggests that CTCF binding to these sites may be blocked, resulting in further spreading of methylation into the MECP2 promoter. CTCF has been shown to bind to boundaries of XCI in mouse [Filippova et al., 2005] , consistent with this hypothesis. Future experiments could be designed to determine if CTCF binding or expression is deficient in autism brain samples based on these preliminary findings.
Aberrant methylation of MECP2 was more difficult to assess in females with autism because of the fewer number of brain samples currently available and the problem of primer bias toward the methylated allele of the highly CpG-rich MECP2 promoter. Interestingly, female autism brain samples showed less primer bias than control female samples, presumably because of the aberrant methylation patterns reflected by the increased number of alleles not easily defined as active or inactive. Since female autism brain samples have also been observed to have aberrantly reduced MeCP2 expression in frontal cortex in addition to males, future studies with novel methods to determine aberrant MECP2 methylation with greater sensitivity in females are warranted.
Our study is novel in the examination of XCI patterns of individual alleles by bisulfite sequencing in addition to the commonly used AR methylation test that relies on restriction enzymes followed by PCR. While both methods revealed XCI in females, important insights into the number of individual methylation sites that are required for silencing AR and MECP2 on the inactive X chromosome were revealed exclusively by bisulfite sequencing, in which 50% methylation of CpG sites on a single allele appeared sufficient for inactivation. The AR PCR-based method appears to be more accurate for determining XCI ratios as the number of cells sampled is much higher and PCR primers are not biased toward the methylated allele in CpG-rich promoters. However, since the methyl sensitive restriction enzyme HpaII only targets two of the available CpG sites in AR exon 1 that are methylated an average of 90% of the time (data not shown), there is expected to be a roughly 10% false-positive rate expected for Xa by the conventional PCR-based assay of AR methylation.
Our data showing insignificant differences in XCI ratios between autism and control females or mothers of autism males are not consistent with a prior report that suggested frequent XCI skewing in autism females and their mothers [Talebizadeh et al., 2005] . The differences in the two studies can likely be explained by differences in the small samples and different methodologies. Our small study is consistent with a recent very large study of 543 mothers and 163 females with ASD that also did not observe significant differences in XCI skewing in families with ASD [Gong et al., 2008] . These studies make ASD mothers distinct from X-linked MR carrier mothers, who have a high frequency of skewed XCI [Plenge et al., 2002] .
Recent evidence has implicated de novo genetic defects in autism [Marshall et al., 2008; Sebat et al., 2007] . We propose that de novo mutations and specific epigenetic alterations, such as increased MECP2 promoter methylation in autism males, contribute substantially to the autism phenotype through dysregulation of genes important in brain development and function. One important next step is to use genomic approaches to assess both global and gene-specific epigenetic changes in multiple autism tissues. Identification of these molecular defects holds promise for the creation of diagnostic tests and eventually therapeutic targets. 
